A Nationwide Study on the Incidence of Breast Cancer in Korean Women with Osteoporosis Receiving Raloxifene Treatment

PURPOSE: Raloxifene is a selective estrogen receptor modulator (SERM), and raloxifene treatment for osteoporosis is reimbursable under the Korean National Health Insurance. Evidence suggests that SERMs use reduces the risk of breast cancer in Asian population. Herein, we retrospectively investigated...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Breast Cancer
Prif Awduron: Lee, Jihyoun, Lee, Ji Sung, Lee, Jong Eun, Kim, Zisun, Han, Sun Wook, Hur, Sung Mo, Choi, Young Jin, Park, Sungmin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Korean Breast Cancer Society 2021
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8250100/
https://ncbi.nlm.nih.gov/pubmed/34128366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2021.24.e28
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg